{'fraction_non_alphanumeric': 0.01955671447196871, 'fraction_numerical': 0.000651890482398957, 'mean_word_length': 5.316872427983539, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
First Investigation of Gadolinium-Based Nanoparticles for Radiosensitization and Enhanced Imaging on the Australian MRI-linac

High atomic number nanoparticles have the capacity to boost the therapeutic efficacy of radiotherapy by enhancing tumor-localized radiation damage. AGuIX® is a gadolinium-based nanoparticle that has been shown to increase survival times compared to radiotherapy alone in pre-clinical animal studies. In addition to its high atomic number, gadolinium also provides strong positive contrast in magnetic resonance imaging (MRI) and is able to cross the blood-brain barrier where disrupted by a tumor.Here we report on the progress of the first study of AGuIX using an integrated linear accelerator (linac) and MRI scanner. The Australian MRI-Linac is a dedicated research facility combining a linear accelerator for delivery of therapeutic radiation with a custom-designed 1 T magnet, allowing MR images to be acquired during treatment. This work demonstrates the imaging and irradiation capability of the Australian MRI-linac on a rat brain tumor model to extend studies that were previously performed with separate MRI and radiotherapy.The MRI contrast provided by AGuIX not only aids delineation of the tumor target for verification and/or adaptation of the treatment plan, but can also monitor the uptake of gadolinium in the tumor to optimize the treatment delivery time to achieve radio-therapeutic gain from radio-enhancement effects.This work paves the way for a clinical trial of AGuIX® in Australia